Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug
By Ben Glickman
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
The companies' drug Tivdak had previously been granted accelerated approval by the U.S. Food and Drug Administration, which allows quicker approval for drugs addressing a serious unmet need. The FDA's full approval covers Tivdak in the treatment of recurrent or metastatic cervical cancer.
Danish biotechnology company Genmab and Pfizer-owned Seagen codeveloped Tivdak under a cost- and profit-sharing agreement.
Tivdak has had accelerated approval from the FDA for cervical-cancer treatment since 2021.
Genmab and Pfizer said Monday that the antibody-drug conjugate had been approved to treat patients who have disease progression on or after chemotherapy, meaning it is a second-line treatment.
The approval was based on results from a Phase 3 trial of Tivdak, which met its primary endpoint of overall survival as well as its secondary endpoints, the companies said.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 29, 2024 19:08 ET (23:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks